ArticleDiscover oncology2025
Mapping research hotspots and trends in hepatocellular carcinoma nanomedicine: a bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status and Emerging Trends in Global Research on Liposome Therapy for Hepatocellular Carcinoma: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a prevalent cancer globally with a poor prognosis. Nanomedicine applications are expected to enhance early detection, improve cytotoxic drug utilization, and improve HCC prognosis. This study aims to conduct a comprehensive bibliometric analysis of research on nanomedicines in HCC, focusing on current hotspots and exploring future development directions. By searching Web of Science, we collected 4,372 English-language articles from January 1, 2012 to October 31, 2022. China emerged as the leading contributor with 2,473 publications (55.6%), followed by the US (299, 6.8%) and India (284, 6.5%). Sun Yat-sen University had the highest number of publications. The most cited journal was the INTERNATIONAL JOURNAL OF NANOMEDICINE, and BIOMATERIALS was the most influential based on H/g/m indices. Key research areas included NANOPARTICLES (11% of keyword occurrences), HEPATOCELLULAR-CARCINOMA (8% ), and DRUG-DELIVERY (6%). in-vitro drug-delivery research remains a potential area. This study reveals that nanomedicines have significant potential in improving HCC early detection, drug-use efficiency, and prognosis. Encapsulating cytotoxic drugs in nanoparticles is a predominant research hotspot, while nanoparticle toxicity's impact on human systems may be a promising future direction. These findings provide valuable insights for guiding future research and clinical translation in HCC nanomedicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.